Non-coding RNAs (ncRNAs), once considered the 'dark matter' of the genome, have now emerged as pivotal regulators in cancer ...

HonorHealth Research Institute recently treated the first patient in a 50-site international clinical trial that will test a ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, presented data today from a study showing that its ...

A combination of pertuzimab and Enhertu can slow disease progression and improve survival in people with HER2-positive ...

Researchers from the University of Eastern Finland, Aalto University and the University of Oulu have developed a new ...

Researchers have shown that activation of the protein YAP, known to help cancer cells survive treatment, behaves very ...

Some people with early stage cancers may be able to skip surgery after being treated with the immunotherapy drug dostarlimab, ...

A new study shows promising results for treating certain cancers with immunotherapy and completely avoiding surgery, ...

HonorHealth Research Institute's new downtown Phoenix laboratory has produced its first study, centered on a promising new ...

The pre-analytical workflow is one of the primary considerations in the successful use of liquid biopsies for cancer ...

Boehringer Ingelheim’s drug candidate for human epidermal growth factor receptor 2 (HER2)-mutated non-small cell lung cancer ...